Qureight expands with addition of second site, to accommodate rapid growth and ongoing development of chest Foundation Model
Deep Learning-derived Fibrotic and Inflammatory Phenotypes Predict Lung Function Across Idiopathic and Connective-tissue-related Interstitial Lung Disease
2026 ATS abstract
AI-Based Quantification of Pulmonary Blood Volumes From CT Pulmonary Angiography Helps Screen for Pulmonary Hypertension
2026 ATS abstract
Structure-function Coupling and Quantitative Imaging Biomarkers in Polymyositis Dermatomyositis Associated Interstitial Lung Disease
2026 ATS abstract
Correlation Between Baseline FVC And Subsequent Longitudinal Change In Real-world IPF Datasets: Implications For FVC Change Prediction
2026 ATS abstract
Imaging-Physiology Dissociation and the Role of Pulmonary Vasculature in Systemic Sclerosis-Associated ILD
2026 ATS abstract
Buloxibutid’s Efficacy in the Phase 2a Air IPF Trial: Comparative Analysis of Baseline Characteristics of Indian Versus World Cohorts
2026 ATS abstract
Associations Between Ground Glass Opacity, Fibrosis and Lung Function in Idiopathic Pulmonary Fibrosis
2026 ATS abstract
Deep Learning-based HRCT Assessment of Baseline Disease Severity in the Deupirfenidone Elevate IPF Trial: Comparison With a Well-Characterised IPF Population
2026 ATS abstract
Synthetic Control Arms in Respiratory Trials: A Smarter Path to Faster Drug Development
Qureight closes $20 million Series B financing
Qureight to highlight advances in AI-powered quantitative imaging biomarkers for respiratory clinical trials at ERS
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight establishes Scientific Advisory Board focused on pulmonary hypertension
Qureight to showcase the use of AI-driven imaging in transforming respiratory disease research and drug development at ATS 2026 International Conference
Meet Miguel: Principal Machine Learning Scientist at Qureight
Meet Amy: Turning Data into Clinical Insight at Qureight
